Journal of Basic and Clinical Pharmacy received 13553 citations as per google scholar report
Helicobacter pylori (H. pylori) infection is the leading cause for the
development of chronic active gastritis, gastroduodenal ulcers, gastric
mucosa-associated lymphoid tissue lymphoma and gastric cancer. As
a result, several eradication regimens for H. pylori infection have been
recommended by national and international guidelines. These regimens
have been repeatedly modified over the years to overcome the evolving
resistance of H. pylori strains to antibiotics. Recently, the Hellenic Society
of Gastroenterology convened a consensus meeting and recommended
that a concomitant non-bismuth quadruple regimen of a Proton Pump
Inhibitor (PPI), amoxicillin, clarithromycin, and metronidazole for at
least 10 days be the preferred first-line therapy in Greece, because it is
associated with higher H. pylori eradication rates. Non-bismuth triple
regimens have showed superior effectiveness in several trials and are
now a feasible alternative, particularly in countries where bismuth is
unavailable, such as Greece.